Abbisko of Shanghai Raises $70 Million for Novel Oncology-Immunocology Candidates
publication date: Mar 25, 2020
Abbisko Therapeutics, a Shanghai novel drug biopharma, raised $70 million in a Series C financing led by Singapore's Temasek. The company has four clinical programs underway, and it intends to expand its discovery pipeline, which consists of small molecule targeted oncology and immuno-oncology candidates. In the last year, Abbisko has started clinical trials of two internally discovered candidates after IND approvals in the US, China and Taiwan. It has also in-licensed two clinical stage assets, one from X4 Pharma and the other from AstraZeneca. More details....
Stock Symbol: (NYSE: AZN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.